ERC Grant

Daniel Andergassen, an independent Junior Group Leader at the Institute of Pharmacology and Toxicology at TU Munich, has been awarded a prestigious Starting Grant from the European Research Council (ERC). This grant will support an ambitious research program focused on understanding the molecular mechanism behind sex differences observed in heart failure. A specific emphasis will be on genes that escape X chromosome inactivation in females, resulting in a higher gene dosage compared to males. This fundamental research will deepen our understanding of the molecular mechanisms underlying sex bias in heart failure and aims to develop RNA-based therapies for sex-specific treatments.